Inappropriate Prescribing of Proton-pump Inhibitor is it Associated With the Burden of Comorbidities in Older Patients?

Geriatric Disorder Clinical Trial

— IPP SA  

Official title:

Inappropriate Prescribing of Proton-pump Inhibitor is it Associated With the Burden of Comorbidities in Older Patients Over 75 Years Old ?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02841852
• Other study ID #: RC13_0262
• Status: Completed
• Phase: N/A
• First received: July 20, 2016
• Last updated: July 25, 2016
• Start date: January 2014
• Est. completion date: July 2014

Study information

• Verified date: July 2016
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santéFrance: Commission nationale de l'informatique et des libertés
• Study type: Observational

Clinical Trial Summary

Proton pump inhibitors (PPIs) are one of the most frequently prescribed classes of drugs in the world and the most effective drugs available to reduce gastric acid secretion. However, studies have shown that PPIs are not always prescribed with a clear indication. Indeed, between 25% and 86% of older individuals taking a PPI have been overprescribed these medications. In older patients, overprescribing of a PPI is associated with increases in morbidity, adverse drug events, hospitalization, and mortality. The hypothesis is that overprescription of PPIs is associated with the individual multimorbidities in older patients evaluated using the multimorbidities group criteria included in the CIRS. The aim of the present study was to establish a relationship between overprescribing of PPIs and multimorbidities in older patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Patients of 75 years or more

• Patients hospitalized in geriatric short stay

• Patients with an inhibitor therapy proton pump short geriatric entry

• Patients who have given their written consent

Exclusion Criteria:

• Patients who have expressed their inability or refusal to sign an informed consent

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Geriatric Disorder

Locations

Country	Name	City	State
France	Centre Hospitalier de St Nazaire	Saint Nazaire

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Burden of comorbidities	Burden of comorbidities is assessed by the CIRS (Cumulative Illness Rating Scale)	48 hours after the entry into acute geriatric medicine	No